A U.S. investigative study team from Vanderbilt University's School of Medicine in Nashville, Tennessee, have unveiled a positive relationship between longer length of survival in melanoma, renal cell carcinoma, and non-small cell lung cancer patients treated by immune checkpoint inhibitors. Following treatment with PD-1 and/or PD-L1 inhibitors, most of the 217 patients studied had a survival period of more than 2 years, and "no obvious long-term adverse cardiometabolic signals were noted.
To read more about this study, click here.
Study mentioned: Patrinely JR Jr., Young AC, Quach H, et al. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. European Journal of Cancer 2020; 135:211-220. DOI: https://doi.org/10.1016/j.ejca.2020.05.005
No comments:
Post a Comment